Novo Nordisk Q3 results: Ozempic maker’s profit falls 27%; cuts 9,000 jobs
Danish pharmaceutical giant Novo Nordisk, the maker of obesity drugs Ozempic and Wegovy, lowered its 2025 sales outlook for the fourth time this year on Wednesday after reporting tepid third-quarter results.The company, which appointed Mike Doustdar as CEO in August, now expects full-year sales growth of 8 to 11 per cent, down from a previous…